EKF Diagnostics Holdings Plc (EKF) - Total Assets
Based on the latest financial reports, EKF Diagnostics Holdings Plc (EKF) holds total assets worth GBX82.43 Million GBX (≈ $10.03K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EKF book value for net asset value and shareholders' equity analysis.
EKF Diagnostics Holdings Plc - Total Assets Trend (2001–2024)
This chart illustrates how EKF Diagnostics Holdings Plc's total assets have evolved over time, based on quarterly financial data.
EKF Diagnostics Holdings Plc - Asset Composition Analysis
Current Asset Composition (December 2024)
EKF Diagnostics Holdings Plc's total assets of GBX82.43 Million consist of 34.9% current assets and 65.1% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 17.5% |
| Accounts Receivable | GBX6.28 Million | 7.7% |
| Inventory | GBX7.39 Million | 9.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX5.05 Million | 6.2% |
| Goodwill | GBX23.88 Million | 29.2% |
Asset Composition Trend (2001–2024)
This chart illustrates how EKF Diagnostics Holdings Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EKF Diagnostics Holdings Plc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EKF Diagnostics Holdings Plc's current assets represent 34.9% of total assets in 2024, an increase from 3.8% in 2001.
- Cash Position: Cash and equivalents constituted 17.5% of total assets in 2024, up from 0.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, a decrease from 95.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 29.2% of total assets.
EKF Diagnostics Holdings Plc Competitors by Total Assets
Key competitors of EKF Diagnostics Holdings Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.54 Billion |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.72 Billion |
|
Guangdong Transtek Medical Electronics Co Ltd
SHE:300562
|
China | CN¥1.42 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$15.57 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
EKF Diagnostics Holdings Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.62 | 4.60 | 1.74 |
| Quick Ratio | 3.47 | 3.08 | 1.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX24.71 Million | GBX19.33 Million | GBX15.15 Million |
EKF Diagnostics Holdings Plc - Advanced Valuation Insights
This section examines the relationship between EKF Diagnostics Holdings Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 1.1% |
| Total Assets | GBX81.75 Million |
| Market Capitalization | $1.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values EKF Diagnostics Holdings Plc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: EKF Diagnostics Holdings Plc's assets grew by 1.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for EKF Diagnostics Holdings Plc (2001–2024)
The table below shows the annual total assets of EKF Diagnostics Holdings Plc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX81.75 Million ≈ $9.95K |
+1.11% |
| 2023-12-31 | GBX80.85 Million ≈ $9.84K |
-9.45% |
| 2022-12-31 | GBX89.29 Million ≈ $10.86K |
-22.44% |
| 2021-12-31 | GBX115.12 Million ≈ $14.01K |
+13.68% |
| 2020-12-31 | GBX101.27 Million ≈ $12.32K |
+16.23% |
| 2019-12-31 | GBX87.13 Million ≈ $10.60K |
+7.06% |
| 2018-12-31 | GBX81.38 Million ≈ $9.90K |
+5.47% |
| 2017-12-31 | GBX77.16 Million ≈ $9.39K |
-6.40% |
| 2016-12-31 | GBX82.43 Million ≈ $10.03K |
+14.67% |
| 2015-12-31 | GBX71.89 Million ≈ $8.75K |
-47.05% |
| 2014-12-31 | GBX135.78 Million ≈ $16.52K |
+123.60% |
| 2013-12-31 | GBX60.72 Million ≈ $7.39K |
+8.98% |
| 2012-12-31 | GBX55.72 Million ≈ $6.78K |
-5.14% |
| 2011-12-31 | GBX58.73 Million ≈ $7.15K |
+63.24% |
| 2010-12-31 | GBX35.98 Million ≈ $4.38K |
+462.44% |
| 2009-12-31 | GBX6.40 Million ≈ $778.33 |
+11.48% |
| 2008-12-31 | GBX5.74 Million ≈ $698.15 |
+3.11% |
| 2007-12-31 | GBX5.57 Million ≈ $677.10 |
+7.83% |
| 2006-12-31 | GBX5.16 Million ≈ $627.94 |
+6.57% |
| 2005-12-31 | GBX4.84 Million ≈ $589.25 |
-27.25% |
| 2004-12-31 | GBX6.66 Million ≈ $809.96 |
+5.23% |
| 2003-12-31 | GBX6.33 Million ≈ $769.69 |
+1033.69% |
| 2003-06-30 | GBX558.00K ≈ $67.89 |
-91.32% |
| 2002-12-31 | GBX6.43 Million ≈ $782.59 |
+18.06% |
| 2001-12-31 | GBX5.45 Million ≈ $662.86 |
-- |
About EKF Diagnostics Holdings Plc
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that pr… Read more